Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment
Status:
Completed
Trial end date:
2010-06-10
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well sirolimus works as secondary
therapy in treating patients with chronic graft-versus-host disease (GVHD) that did not
respond to prior treatment. Sirolimus may be an effective treatment for chronic GVHD
Phase:
Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium